Who
Pratik S. Multani
Director
Company insider
Files Form 4 as: Director, Erasca; Chief Medical Officer, Oric Pharmaceuticals; Director, Chimerix; Chief Medical Officer, Ignyta; Chief Medical Officer, Fate Therapeutics.
In numbers
- Trades disclosed
- 74
- Buys
- 1
- Sells
- 5
- Bought
- $99K
- Sold
- $229K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 9 Jan 2014
- Last trade
- 26 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —214,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —214,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,532 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,532 at $0.00 | filing |
| 16 Dec 2025filed 17 Dec 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $97K10,720 at $9.06 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,000 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,333 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,333 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 23 May 2025filed 3 Jun 2025 | ERAS ErascaBiotechnology | SEC FORM 4 Code G | —6,200 at $0.00 | filing |
| 23 May 2025filed 3 Jun 2025 | ERAS ErascaBiotechnology | SEC FORM 4 Code G | —6,200 at $0.00 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —35,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —35,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
News
ORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer DataORIC · rttnews.com · 23 Oct 2026Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company StockORIC · themarketsdaily.com · 22 Oct 2026
0 headlines in the last 90 days name Pratik S. Multani; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.